Emergent BioSolutions | EBS - Loan Capital


Emergent BioSolutions reported $446.5M in Loan Capital for its fiscal quarter ending in December of 2023.





Loan Capital Change Date
Acadia Pharmaceuticals USD 0 0 Mar/2025
Akebia Therapeutics USD 48.25M 609K Dec/2025
ALKERMES USD 285.82M 639K Sep/2024
Alnylam Pharmaceuticals USD 2.48B 1.44B Dec/2025
ANI Pharmaceuticals USD 291.84M 5.84M Dec/2025
BioMarin Pharmaceutical USD 597.18M 513K Dec/2025
Coherus Biosciences USD 294.85M 2.33M Mar/2025
Emergent BioSolutions USD 446.5M 1.7M Dec/2023
Exact Sciences USD 2.33B 9.34M Sep/2025
Glaxosmithkline GBP 20.02B 4.72B Sep/2025
Heron Therapeutics USD 149.65M 157K Sep/2024
Ionis Pharmaceuticals USD 1.9B 1.87B Dec/2025
Ironwood Pharmaceuticals USD 583.99M 14.83M Dec/2024
Lexicon Pharmaceuticals USD 56.11M 2.54M Jun/2025
Lonza CHF 4.24B 602M Dec/2024
Merck USD 39.97B 6B Sep/2025
Moderna USD 610M 584M Dec/2025
Myriad Genetics USD 119.5M 60.2M Sep/2025
Nektar Therapeutics USD 107.51M 10.35M Jun/2024
Neurocrine Biosciences USD 169.5M 500K Mar/2023
Pacira USD 372.19M 4.53M Dec/2025
Pfizer USD 57.41B 93M Sep/2025
PTC Therapeutics USD 2.03B 193.22M Dec/2025
Sanofi EUR 15.72B 2.45B Dec/2025
Sarepta Therapeutics USD 828.97M 206.17M Dec/2025
United Therapeutics USD 100M 100M Jun/2024
Vanda Pharmaceuticals USD 3.15M 3.15M Dec/2024
Xoma USD 94.38M 7.82M Sep/2025